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Abstract
Juvenile myelomonocytic leukemia (JMML) is a rare aggressive myelodysplastic/myeloproliferative neoplasm of early
childhood, initiated by RAS-activating mutations. Genomic analyses have recently described JMML mutational landscape;
however, the nature of JMML-propagating cells (JMML-PCs) and the clonal architecture of the disease remained until now
elusive. Combining genomic (exome, RNA-seq), Colony forming assay and xenograft studies, we detect the presence of JMML-
PCs that faithfully reproduce JMML features including the complex/nonlinear organization of dominant/minor clones, both at
diagnosis and relapse. Further integrated analysis also reveals that although the mutations are acquired in hematopoietic stem
cells, JMML-PCs are not always restricted to this compartment, highlighting the heterogeneity of the disease during the initiation
steps. We show that the hematopoietic stem/progenitor cell phenotype is globally maintained in JMML despite overexpression of
CD90/THY-1 in a subset of patients. This study shed new lights into the ontogeny of JMML, and the identity of JMML-PCs,
and provides robust models to monitor the disease and test novel therapeutic approaches.
Introduction
Juvenile myelomonocytic leukemia (JMML) is a rare and
aggressive childhood myelodysplastic/myeloproliferative
neoplasm (MDS/MPN) thought to be initiated by the activa-
tion of the RAS signal transduction pathway due to germline
or somatic mutations in genes encoding RAS (NRAS, KRAS)
or RAS-pathway regulators (PTPN11 encoding the SHP2
cytoplasmic phosphatase, and less frequently NF1 or CBL)
[1, 2]. A hallmark of JMML is a hypersensitivity to
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granulocyte macrophage-colony stimulating factor (GM-
CSF), which leads to enhanced in vitro proliferation of
monocyte-macrophage colonies in the absence of exogenous
colony stimulating factor [3, 4]. In patients, this excessive
proliferation of monocytes and granulocytes leads to hepa-
tosplenomegaly, lymphadenopathy, skin rash, and respiratory
failure. JMML is usually rapidly fatal due to multiorgan
failure or progression towards acute myeloid leukemia (AML)
unless allogeneic hematopoietic stem cell transplantation
(HSCT) is performed [5]. However, there is a signiﬁcant risk
of post-HSCT recurrence, and overall survival only reaches
50–60% [6].
Previous studies [7–9] based on whole exome sequencing
(WES) have uncovered additional genetic abnormalities in
about 65% of sporadic JMML cases and demonstrated the
association between JMML outcome and mutational proﬁle.
Indeed, the presence of more than one RAS-activating
mutation (RAS double mutants) distinguishes very aggres-
sive JMML with an increased risk of AML progression [7–9].
If the genomic landscape of JMML is relatively well
deﬁned today, very little is known about the origin of
JMML, the JMML-propagating cell (JMML-PC) or the
clonal evolution in JMML, those being, all crucial steps to
improve the management of children with JMML.
Although this syndrome is predominantly characterized
by granulo-monocytic lineage involvement, JMML also
shows evidence of multilineage involvement [10]. Throm-
bocytopenia is a common feature, high fetal hemoglobin
levels are found in about 60% of patients, reﬂecting a
contribution of the erythroid lineage [11], and cases of
JMML evolving into a B lymphoid blast crisis have been
reported [12]. JMML is thus considered a disease of the
hematopoietic stem/progenitor cell (HSPC) compartment.
However, the putative leukemia-propagating cells have not
yet been characterized, and evidence of clonal hetero-
geneity, with lymphoid lineage cells harboring RAS-
activating mutations in some patients but not in others,
suggests that the cell type affected by the initiating mutation
may vary between patients [2].
Patient-derived xenografts (PDX) provide an invaluable
tool to functionally assess tumor samples for leukemia-
propagating cell potential. However, limited data are
available concerning the capacity of primary JMML PDX
to engraft in immunodeﬁcient mice, and whether addition
of exogenous human GM-CSF is required for JMML
to engraft is not clear [13–16]. Moreover, no study to
date has established the robustness of the JMML xeno-
transplantation model with regard to the reproducibility
of the disease, clonal composition, and clonal evolution
in mice. Importantly, the identity of the cells capable
of propagating JMML in vivo at diagnosis and at relapse
has yet to be deﬁned. Lastly, the cell type in
which oncogenic mutations arise and the dynamics of
clonal expansion during hematopoietic differentiation
remains to be determined.
In this paper, we aimed to address these questions by
using a combination of whole-exome and targeted deep
next-generation sequencing, single-cell colony analysis, and
cell sorting as well as xenotransplantation experiments with
17 JMML samples obtained from 15 patients.
Material and methods
Patient samples
The cohort included 36 patients with JMML (19 males, 17
females) aged 3 months to 13 years (median 2.2 years)
(Supplementary Table S1). All patients fulﬁlled the WHO
consensus JMML criteria [17]. Most patients had sporadic
JMML with mutations in PTPN11 (PTPN11-JMML; n=
13), NRAS (NRAS-JMML; n= 14), KRAS (KRAS-JMML;
n= 5), or other genes (n= 3). An additional patient (#123)
had a germline PTPN11 p.N308T mutation, in line with
Noonan syndrome features.
JMML patient samples (BM, n= 36; peripheral blood n
= 2) were collected in a diagnostic setting. All children’s
samples were obtained after parents had given their written
informed consent. This study was approved by the institu-
tional review board of the French Institute of Health and
Medical Research (INSERM) (IORG0003254) in accor-
dance with the Helsinki declaration.
Clinical data and genetic proﬁles obtained from 15 of
these JMML patients that were studied using xeno-
transplantation models are shown Table 1. Pulmonary
involvement was determined as clinical signs of respiratory
distress ± documented leukemia inﬁltration. Blast crisis was
deﬁned as the presence of ≥20% blasts assessed by cyto-
morphological examination of the BM. A second RAS-
activating mutation was observed in 6/15 patients including
duplication of the oncogenic mutation due to acquired
uniparental disomy (aUPD) in two cases.
BM of healthy age-matched children (n= 19) was
obtained from intrafamilial BM transplantation donors. The
collection and use of these samples were approved by the
Institutional Review Board of “Hôpitaux Universitaires Paris
Nord Val-de-Seine,” Paris 7 University, AP-HP), (IRB:
00006477), in accordance with the Helsinki declaration.
Animals
All animal experiments were performed at the Francis Crick
Institute in accordance with UK Home Ofﬁce and CRICK
guidelines and were undertaken under the Home Ofﬁce
project license PLL 70/8904. NOD/SCID/IL2rγ−/− (NSG)
mice and NOD/SCID/IL2rγ−/−/IL-3/GM/SF (NSG-S) mice
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were originally a kind gift of Dr Leonard Shultz (The
Jackson Laboratory) and since then have been bred at the
Francis Crick Institute Biological Resource facility. These
mice were genotypes on arrival and on regular basis
thereafter using the genotypic protocols provided by the
Jackson laboratory.
Table 1 Clinical data and detailed genetic proﬁles obtained by combining karyotype, genome-wide DNA array analysis, whole exome (WES) and
targeted next-generation sequencing for the 15 JMML patients who were studied using xenotransplantation in mouse
Patient # #50  #53 #88 #95 #99 #154 #123 #73 #91 #92 #109 #152 #29 #66 #81
Gender F M M M M F F M F F F M F F M
Age at diagnosis (years) 0.7 2.2 2.8 8.1 2.5 0.8 0.3 4.2 2.9 4.5 13.3 0.8 1.1 2.1 0.3
Platelets at diagnosis 75 23 26 51 30 128 155 84 72 197 180 140 153 82 78
WBC (109/L) at diagnosis 57 71 17 6 4 42 54 67 48 51 14 7 19 37 26
HbF elevated for age Yes Yes Yes Yes Yes No ND ND ND Yes No No No Yes ND
LIN28B  overexpression Yes Yes Yes Yes Yes No No No Yes Yes No No No Yes No
Pulmonary involvment No No Yes ND No ND Yes No Yes Yes ND No Yes Yes Yes
HSCT Yes Yes Yes Yes Yes Yes No Yes Yes Yes Yes No Yes Yes Yes
Blast crisis No No No No No No No Yes Yes Yes Yes No No No No
Relapse post HSCT No No No No No No N/A No No Yes No N/A Yes Yes No
Death No Yes No No No No No No No Yes No No No Yes No
Genetic group
PTPN11 aUPD            
NRAS aUPD
KRAS
CBL
NF1
RRAS
ASXL1
SETBP1
JAK3 *
chromosome 7
PDE8A
DYNC1H1
ITPR3
COL22A1
chromosome Y
KRT1
EDAR
TNS3
CPT1A
PLXNB2
IL33
MRGPRX2
ATOH1
SMC1A I
NPM1
SRGAP1
SAP130
LARP1B
chromosome 6
RAC2
NACAD
RUNX1
FANCA
ABI1
NADK
NKAP
CPT1B
ZNF592
M Male PTPN11, somatic SNV, somatic 2 mutations on the gene
F Female PTPN11, germline SNV, germline * subclonal (VAF <20%)
NRAS Indel, somatic I Hemizygous alteration
KRAS CNV, somatic loss
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Each column highlights the condensed data for a single patient at diagnosis
WBC whole blood cell count, HbF fetal hemoglobin, HSCT hematopoietic stem cell transplantation, ND not done, N/A not applicable,
SNV single-nucleotide variation, CNV copy number variation, aUPD acquired uniparental disomy, VAF variant allele frequency
Dash: two mutations on the same gene
*Subclonal alteration (VAF < 20%); I: Hemizygous alteration
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Xenotransplantation
Prior to transplantation, NOD/SCID/IL2rγ−/− (NSG) mice
and NOD/SCID/IL2rγ−/−/IL-3/GM/SF (NSG-S) mice (aged
8–12 weeks old), sex matched/patient (female or male)
received a sublethal dose of radiation (350–375 cGy) from a
cesium-137 source. Direct intra-BM injection was per-
formed in the tibia with 15 × 103 BM CD34+ cells from
patients and healthy donors. Number of mice injected per
samples varied between samples and were dependent on the
primary cells available (from two to six mice). Neither
exclusion criteria nor randomization were performed. The
investigator was not blind to the group. Engraftment was
assessed at sacriﬁce (6–12 weeks) and the BM cells (pooled
femurs, tibias, and 1 pelvis) were immuno-phenotyped for
the presence of mCD45, hCD45, hCD33, hCD19, and
hCD3 (BD Biosciences, Oxford, UK) cell populations. Live
cells were stained and sorted on hCD45 phenotype using
FACS Aria SORP (BD Biosciences, Oxford, UK) or sorted
by magnet isolation using EasySep™ Mouse/Human
chimera isolation kit (cat no. 19849, Stem cell technologies,
Inc, Vancouver, Canada). Isolated CD45+ cells were
washed in PBS and plated into methylcellulose as men-
tioned below and/or pelleted in order to later perform
genomic analysis or used for secondary transplantation
experiment. In addition, one pelvis, one lobe of lung and
the spleen were ﬁxed for immunochemistry/immuno-
ﬂuorescence and 105 cells from harvested BM were cytos-
pinned, and then ﬁxed in methanol on a slide for later
analysis using May–Grunwald–Giemsa staining. For sec-
ondary transplantation, between 1 and 3.7 × 106, human
CD45+ cells were injected into sublethally irradiated reci-
pient mice (NSG or NSG-S).
Depositing dataset
Whole genome sequencing data were available via
ArrayExpress database: http://www.ebi.ac.uk/arrayexpress,
Accession number E-MTAB-6461 (patients) and E-MTAB-
6467 (xenograft samples). For SNP/CGH array: Accession
numbers E-MTAB-3729 (SNP array) and E-MTAB-6468
(CGH+ SNP array).
Statistics
Differences between groups were tested using the
Mann–Whitney test (two groups) or by using multi-
variable one-way ANOVA unpaired analysis corrected
for multiple comparisons (multiple groups). All analyses
were performed with Prism software. version 6.0
(GraphPad, La Jolla, CA, USA). Statistical signiﬁcance
was deﬁned as p value < 0.05. Statistical value is provided
in each ﬁgure.
Supplementary material and methods section is available in
supplementary information including reagents and resources
used in this paper (see Table S8).
Results
JMML bone marrow cells maintain HSPC phenotype
JMML BM samples (n= 31) (Supplementary Table S1)
were compared with BM from age-matched healthy chil-
dren (n= 19). Hematopoietic stem cells (HSCs), multi-
potent progenitors (MPPs), lymphoid-primed multipotent
progenitors (LMPPs), common myeloid progenitors
(CMPs), granulocyte-macrophage progenitors (GMPs), and
megakaryocyte-erythroid progenitors (MEPs) were identi-
ﬁed using multiparametric FACS analyses based on pre-
viously deﬁned markers [18] (Fig. 1 and Supplementary
Fig. S1A). JMML BM displayed a signiﬁcant expansion of
the LMPP and GMP compartments (Fig. 1a and Supple-
mentary Fig. S1B). This expansion was mostly accounted
for by PTPN11-mutated JMML, which also showed a larger
percentage of myeloid progenitors compared with healthy
BM within the CD34+CD38+ compartment (Supplementary
Fig. S1C), consistent with the major granulo-monocytic
expansion observed in patients with this subtype of JMML.
However, despite the expected LMPP/GMP trend, all
hematopoietic compartments (phenotypically and molecu-
larly deﬁned) were present in most JMML samples, as in
their healthy counterparts (Fig. 1b and Supplementary
Fig. S1D), thus showing that the HSPC phenotype is
globally maintained in bone marrow of JMML patients.
This analysis also revealed an aberrant upregulation of
CD90/Thy1 expression within the CD34+CD38− fraction in a
subset of JMML cases, that persisted in the CD34+/38+
progenitor fraction (Fig. 2a, b and Supplementary Table S2),
and could be tracked down to the monocyte population in
some patients (not shown). Within CD34+/38+ progenitors,
aberrant CD90 expression was mostly found in the GMP-like
population, with 15/27 (55%) of JMML cases showing
ectopic CD90 expression in more than 30% of the GMP cells.
This was conﬁrmed as a transcriptional deregulation by
RNAseq analysis (data not shown).
JMML is recapitulated in both NSG and NSG-S mice
In order to functionally assess the leukemia-propagating cell
potential, xenotransplantation of cells from 15 genetically
deﬁned JMML was performed (Table 1 and Supplementary
Table S1). Consistent with the speciﬁc hypersensitivity of
JMML myeloid progenitors to GM-CSF [3], the treatment
of immunodeﬁcient mice with human GM-CSF has
been shown to favor the engraftment of JMML cells [15].
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Xenotransplantation of cells from ten JMML samples at
diagnosis and two JMML samples at relapse was thus per-
formed in parallel in two immunocompromised mouse strains
NSG mice and NSG-S mice (also called NSG-SGM3), which
is humanized to express the cytokines GM-CSF, SCF and IL-
3 (Supplementary Table S1). Two more JMML samples were
injected in NSG mice only, and one in NSG-S mice only.
In compliance with UK Home Ofﬁce guidelines, we ﬁrst
investigated, using samples from a small cohort of four
patients (see Supplementary Fig. S2A, B), how long mice of
each strain could be maintained in a healthy state post
transplantation. The overall sickness curve showed that
NSG-S mice had to be sacriﬁced after ~6 weeks, compared
with 12 weeks for NSG mice (Supplementary Fig. S2A). At
6 weeks, the level of engraftment in NSG mice was below
the detection threshold (<0.1%) for two out of the four
xenografts tested (Supplementary Fig. S2B). Accordingly,
we decided to sacriﬁce the NSG-S mice at 6 weeks and the
NSG mice at 12 weeks (or earlier if signs of sickness were
observed in any of the littermates).
In NSG, 4 samples out of 12 tested were below our
threshold (<0.1%) of detection compared with only 1 out of
11 in NSG-S. Only one patient sample (#109) did not
engraft in either mouse models. Two samples that were not
engrafted in NSG at 12 weeks, engrafted in NSG-S mice at
6 weeks. However, in all other cases, engraftment was
detected in both models (Fig. 3a). The kinetics and level of
engraftment observed in NSG and NSG-S, varied between
patients and according to the initiating JMML mutations
(Fig. 3a). Interestingly, despite the maintenance of the
CD90high expression in the cells out of the mice (data not
shown), we could not evidence a higher engraftment
capacity of the CD90high JMML samples tested (see Fig. 3a,
patients 53, 88, 91, and 95).
At sacriﬁce, mouse BM showed characteristic
JMML cytomorphological features, with similar blasts and
Fig. 1 Despite heterogenous distribution, phenotypically and mole-
cularly deﬁned stem/progenitor cell fractions are maintained in JMML.
a Distribution of phenotypically deﬁned HSC, MPP, and LMPP within
the CD34+CD38− population (left panel), and of CMP, GMP, and
MEP within the CD34+CD38+ population (right panel) in BM of
patients with JMML (n= 31) compared with healthy children (n=
19). b Transcriptional validation of phenotypically deﬁned JMML
stem/progenitor cell fractions (n= 14) compared with their normal
counterparts sorted from healthy children BM (n= 4). RNAseq results
are expressed as mean FPKM scores (±SD) for gene transcripts that are
characteristic of the normal counterpart of phenotypically deﬁned stem
(HLF, MPL, ABCB1, and HOXA9) and progenitor cell (CSF1R,
CSF3R, EPO, and GATA1) fractions. See Supplementary Fig. S2 for
gating strategy and RNAseq results for additional genes. Anova
multiple comparison, ****p < 0.0001; ***p < 0.001; **p < 0.01; *p <
0.05; ns not signiﬁcant, BM bone marrow, FPKM fragments per
kilobase million, SD standard deviation
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myelomonocytic cell counts to the native sample (Supple-
mentary Fig. S2D). Engrafted mice also had splenomegaly,
which was more prominent in NSG-S mice (Supplementary
Fig. S2E). Consistent with the pulmonary involvement fre-
quently observed in JMML patients, immunoﬂuorescence
labeling of murine lungs additionally revealed human CD45+
cell inﬁltration after transplantation with some of the JMML
samples (Supplementary Fig. S2F).
Thus, both mouse models recapitulate unique clinical
features of the JMML pathology, with a general faster
engraftment in NSG-S mice highlighting the hypersensi-
tivity of JMML cells to GM-CSF.
JMML xenografts identify multiple JMML-PCs that
may reside in non-HSC fractions
To further conﬁrm the presence of JMML-PCs in the two
models, we tested their self-renewal potential by performing
secondary transplantation of three JMML transplants (#88,
#92, and #99), into the matching mouse strain. In order to
understand whether human cytokines present in NSG-S
would increase engraftment in secondary mice, one JMML
sample (#92), ﬁrst engrafted in an NSG mouse, was cross-
transplanted into an NSG-S mouse. In all cases, successful
secondary engraftment was obtained at 12 weeks (Fig. 3c
and Supplementary Table S3).
Contrary to what was observed with primary transplants,
engraftment was slightly decreased following secondary
transplantation in NSG-S compared with NSG mice despite
the longer time-lapse in NSG compared with NSG-S mice
(12+ 12 weeks for NSG versus 6+ 12 weeks for NSG-S)
suggesting that the self-renewing JMML-PCs are less sen-
sitive to human cytokines.
Overall, our data evidence the presence of self-renewing
JMML-PCs and conﬁrm the robustness of both mouse
models in promoting engraftment and maintaining JMML-
PCs, although NSG mice present some advantages in terms
of survival times.
Having proven the presence of self-renewing JMML-PCs
in JMML samples, we next investigated the nature of these
cells. HSC, MPP, LMPP, CMP, and GMP subfractions
were sorted from ﬁve JMML patients and injected sepa-
rately into NSG mice. NSG mice were preferred to NSG-S
mice since we wanted to reveal JMML long-term propa-
gating cells. In most patients from whom JMML cells
engrafted, xenografts conﬁrmed the presence of JMML-PCs
in the more immature HSC/MPP compartment. Intriguingly,
more committed cells, such as LMPP/CMP/GMP, were also
able to propagate the disease, demonstrating the JMML-PC
capacity of the mature compartment (Fig. 3d). From these
data, it is clear that JMML-PCs are not restricted to the HSC
fractions, and that in the same patients, more than one
subtype of JMML-PCs could be found.
JMML xenografts maintain the JMML mutational
landscape in both mouse models
The mutational landscape of JMML xenografts, investi-
gated by WES, was compared with the patient sample pre
transplantation (Supplementary Tables S4 and S5). The
Fig. 2 CD90 is overexpressed in a subset of JMML. a Representative
ﬂow cytometry plots of a healthy child BM, and patients #92 (NRAS-
JMML) and #95 (PTPN11-JMML) with respectively normal and over/
ectopic expression of CD90/Thy1 across the different hematopoietic
compartments. The ﬁrst column shows CD90 vs CD45RA within the
CD34+CD38− fraction, the middle column shows CD135 vs CD45RA
and last column shows CD90 vs CD45RA within the CD34+CD38+
fraction. Gating of cellular HSPC fractions is indicated. b Percentage
of CD90/Thy1 expressing cells measured by ﬂow cytometry in JMML
compared with healthy children BM within the total CD34+CD38+
fraction, and across the different hematopoietic progenitor compart-
ments CMP, GMP, MEP (see also Supplementary Table S2). Anova
multiple comparison, ****p < 0.0001; ***p < 0.001; ns not signiﬁcant
A. Caye et al.
allelic frequency of the identiﬁed pathogenic variants
(VAF) was further determined using targeted high-
throughput sequencing (Supplementary Table S5).
With an overall correlation rate of 0.77 for VAF mea-
sured before and after transplantation in NSG and NSG-S
mice (Fig. 3e), our data show that xenotransplantation
preserved the overall mutational proﬁle of the native JMML
samples both in terms of clonal diversity and distribution.
Only a few native variants with a low allelic burden
remained undetected in mice (Supplementary Fig. S3),
likely reﬂecting a stochastic process related to the low
number of injected cells rather than to a counter-selection
in mice.
No difference in the mutational landscape was observed
between NSG and NSG-S mice (Fig. 3e, Supplementary
Fig. S3, and Table S5), indicating that the human cytokines
present in the latter, despite stimulating JMML cell growth,
did not impact their clonal distribution. No novel variant
was detected in xenotransplanted mice that was not already
present in the native sample.
Fig. 3 PDX models accurately capture the features and clonal diversity
of the disease and allow to characterize the JMML-PC. a Percentage of
human CD45 out of total BMNCs present in the mouse BM at ter-
mination, in NSG (n= 12 patients, n= 35 mice), and NSG-S (n= 11
patients, n= 27 mice). In each panel, red symbols indicate JMML that
are CD90high (#53, #88, #91, and #95). b The levels of human
engraftment are displayed per mutated gene between the two mice
models. Matching shapes and colors represent the same patient
between the two models. c The level of human CD45 engraftment out
of total nucleated cells in secondary recipients (10 NSG, 8 NSG-S) for
three patients (#88, #92, and #99). Samples harvested from primary
NSG mice were injected into NSG secondary recipient and/or primary
NSG-S into secondary NSG-S. For patient #92, cells harvested from
the NSG primary mouse were injected into either NSG or NSG-S (see
also Supplementary Table S3). d Heat map representation of the level
of engraftment obtained after injection of the different JMML hema-
topoietic fractions (HSC, MPP, LMPP, CMP, GMP) of ﬁve patients
with JMML (#88, #95, #154, #152, and #66). The number of cells
injected per patient and per fraction is displayed for each fraction.
e Correlation of variant allele frequencies (VAF) obtained from the
cells post xenotransplant compared with the native JMML cells from
the patient at diagnostic. Each dot representing one mutation (red dots:
NSG; blue dots: NSG-S). See also Supplementary Fig. S3
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We also conﬁrmed that the cells present in the secondary
transplanted mice had a similar clonal composition to those
present in the original sample (Supplementary Table S5).
JMML subclonal mutation architecture reveals early
clonal dominance
To gain further insight into the clonal structure of JMML,
we identiﬁed the combinatorial patterns of “driver muta-
tions” in individual clones using VAF determined by deep
sequencing of JMML, in combination with the sequencing
of single-cell derived colonies obtained from clonogenic
(colony forming cell, CFC) assays, performed before and
after engraftment in mice (Fig. 4a).
Two groups of JMML could be delineated according to
their clonal architecture. A majority of patients (12/15)
presented at diagnosis with either a single (3/12), or several
mutations co-existing in a unique JMML clone (9/12), as
demonstrated by CFC analysis and/or postulated from ele-
vated VAF (>30%) for all variants (data not shown). This
was consistent with a linear pattern of mutation acquisition,
although in most cases, the order of acquisition of mutations
could not be determined since they were all present in each
clone that could be studied (see example of patient 95,
Supplementary Fig. S4).
In the remaining patients (3/15), JMML showed non-
linear progression with several subclones co-existing at
diagnosis (Fig. 4b, patients 66 and 92 and Supplementary
Fig. S4, patient 88). Interestingly, NSG and NSG-S models
faithfully captured this clonal heterogeneity in all patients,
with all subclones identiﬁed in the xenotransplanted cells
(see CFC assays from NSG or NSG-S mice, Supplementary
Table S6).
We then investigated the dynamics of JMML clonal
architecture during myeloid differentiation by comparing
clonal frequencies in sorted HSC, MPP, LMPP, CMP,
GMP, and MEP cells from ﬁve patients with both types of
clonal architecture, before and after engraftment in mice
(Supplementary Table S1 and Fig. 4a). Whether the
JMML showed linear (n= 2) or branched (n= 3) clonal
evolution, targeted sequencing of sorted fractions
evidenced the presence of all mutations in the HSC or
CD34+CD38− compartment, as well as in more differ-
entiated fractions, with frequencies mirroring those found
in the bulk of mononucleated cells (Supplementary
Table S7). The same was observed when analyzing the
global mutational landscape present in mice injected with
different JMML-PC-containing cell fractions from the
same patient. Not only were all mutations (initiating as
well as additional) found in all cell fractions that could be
tested, but the balance between subclones also seemed to
be preserved in most fractions at diagnosis (Supplemen-
tary Table S7).
These data are consistent with an early dominance of the
leukemic clone during hematopoiesis and suggest that not
only the initiating mutation but also additional ones con-
tribute to this early clonal dominance, with a stable clonal
distribution that remains unaffected during hematopoietic
differentiation.
Two (#66 and #92) of the three patients with a branched
clonal architecture at diagnosis subsequently relapsed.
Patient 66’s JMML displayed branched evolution from a
KRAS-mutated founder clone. A clonal outgrowth was
observed at relapse, with a minor clone at diagnosis
becoming the dominant one (Fig. 4b and Supplementary
Table S6). Whatever the fraction injected in the mice (total
CD34+ cells or sorted HSC, MPP, and LMPP), direct
sequencing of human engrafted CD45+ cells and CFC
analysis out of the mice revealed that the clonal architecture
of the native JMML sample (whether at diagnosis or
relapse) was maintained in mice (Fig. 4b and Supplemen-
tary Table S6).
Patient 92’s JMML also displayed branched evolution
from an NRAS-mutated founder clone with a major sub-
clone having acquired mutations in RAC2 and NACAD and
a minor subclone harboring two distinct mutations in NF1
(Fig. 4b and Supplementary Table S6). At relapse, this latter
subclone gained a mutation in IKZF1 and became dominant
(Fig. 4b and Supplementary Table S6). Here again, when
total CD34+ cells were injected, the clonal architecture of
the native JMML sample was maintained in mice regardless
of the stage at which the JMML was sampled. However,
when HSPC fractions from Patient 92’s relapse sample were
injected in mice, only human CD45+ cells obtained from
HSC- and MPP-injected mice corresponded to the relapse
clone. Indeed, analysis of cells retrieved from the LMPP-
and progenitor fraction-engrafted mice only evidenced the
clone dominant at diagnosis but not the new clone that arose
at relapse (Fig. 4b and Supplementary Table S6). Thus, in
this patient, JMML-PCs, depending on maturational stage,
had two different mutation signatures, the HSCs and MPPs
propagated the relapse clone signature only, whereas the
JMML-PCs with an LMPP/progenitor phenotype harbored
the clone signature at diagnosis. This suggests that the
clonal evolution observed at relapse is associated with a loss
of the engraftment property of the most mature hemato-
poietic fractions.
Discussion
The nature and exact stage of hematopoietic differentiation
of the cell of origin in JMML remains elusive. Better
knowledge of the origin of the JMML-PC as well as its
clonal organization and integration within the hematopoietic
differentiation hierarchy could be instrumental in providing
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insight into the pathogenesis of this severe but still poorly
understood leukemia. Xenotransplantation in immunodeﬁ-
cient mice combined with CFC assays, cell sorting and
genomics is a powerful tool for leukemia-initiating cell
characterization. We therefore decided to evaluate the
engraftment capacity of JMML in immunodeﬁcient mice by
comparing transgenic NSG and NSG-S mice.
In vivo xenotransplantation into NSG and/or NSG-S
mice of samples from 15 JMML cases covering the most
frequent genetic subgroups (i.e., PTPN11, NRAS, and
KRAS) conﬁrmed the capacity of most JMML samples to
engraft in immunodeﬁcient mice [14, 16]. Injection of iso-
lated HSPC fractions in immunocompromised mice
revealed that despite the HSC origin of the whole muta-
tional landscape, JMML-PCs were not restricted to this
fraction but could be present in MPPs, LMPPs and even in
progenitor cells such as CMPs/GMPs. Also, and quite
surprisingly, in samples from the same patient, more than
one subtype of JMML-PCs could be detected, highlighting
the challenge of eradicating these cells in JMML patients.
Importantly, these ﬁndings are not the consequence of
phenotypic unfaithfulness since we show that the HSPC
Fig. 4 Clonal dynamics with time and across hematopoietic differ-
entiation shows early clonal dominance. a Schematic of experimental
procedure followed in order to delineate the origin and clonal archi-
tecture of JMML. All CFCs obtained from these experiments on naïve
JMML (blue icons) or xenotransplanted JMML (brown icons) were
tested for known patient mutations by targeted sequencing. See also
Fig. S4. b Clonal architecture of two JMML samples (#66 and #92), as
determined by combining whole exome sequencing, deep targeted
sequencing, and single-cell derived colony sequencing before and after
xenotransplantation. For each patient, a ﬁsh plot (left) represents clonal
evolution between diagnosis and relapse. In the absence of pre-
leukemia sample allowing to specify the kinetics of clonal emergence,
subclones were represented by default as appearing simultaneously.
Mutations found in each subclone are indicated (see also Supple-
mentary Table S6). The clonal composition in total JMML mono-
nucleated cells (MNCs) at diagnosis or relapse is also represented in
circles. The larger circle represents the founding clone. Smaller circles
inside represent subclones of various size and matching colors with the
ﬁsh plot. Clonal composition and engraftment capacities across
hematopoietic differentiation are represented on the right panels.
Mutations identiﬁed in MNC were screened in sorted fractions before
and after xenotransplantation using Sanger sequencing. Mouse icons
tag fractions that were injected in NSG and/or NSG-S mice. Red
mouse icons indicate successful engraftment whereas gray icons
indicate engraftment failure. Patient (#66) KRAS-JMML showing
branched evolution with independent acquisition of additional muta-
tions targeting ASXL1. The dominant clone at diagnosis or at relapse
was also dominant in corresponding xenografts. Patient (#92) NRAS-
JMML showing branched evolution with independent acquisition of
additional mutations targeting either NF1 or RAC2. At relapse, exome
sequencing performed on the MNC evidenced the gain of an IKZF1
mutation within the clone that became dominant at relapse. Sorted
relapse HSC, MPP, and LMPP engrafted in NSG mice and targeted
sequencing of individual picked CFC obtained from these mice
demonstrated the presence of the dominant relapse clone in HSC and
MPP whereas cells retrieved from the LMPP, CMP, and GMP
engrafted mice only harbored the mutations of the clone that was
dominant at diagnosis but minor at relapse
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hierarchy is preserved in JMML, similar to what has pre-
viously been shown in other types of MDS/MPN [19].
Our data demonstrate the robustness of the JMML
xenotransplantation model and show that both mouse
models not only reproduce major JMML clinical features,
but also respect the native clonal architecture in all three
major genetic groups of sporadic JMML. Such ﬁndings are
in sharp contrast with what has been reported for AML
[19, 20] or T-cell acute lymphoblastic leukemia [21], and
suggests that minor subclones that may have remained
undetected in the native sample either do not exist in JMML
or are not selected differently in mice than in the patient.
Strikingly, the mouse models did not anticipate clonal
evolution observed at JMML relapse. However, the clonal
shift at relapse might well be stochastic, due to the drastic
clonal reduction induced by BM transplantation.
Interestingly, whatever the initiating genetic lesion, GM-
CSF expressed by NSG-S mice leads to a rapid myeloid
expansion, contributing to the aggressive nature of the
malignancy, but does not have a signiﬁcant long-term effect
on self-renewing JMML-PCs. Importantly, NSG-S mice
also do not seem to induce a bias in clonality compared with
NSG, contrary to what might have been expected if human
GM-CSF preferentially “overstimulated” speciﬁc sub-
clones. This highlights that, although GM-CSF hypersen-
sitivity is a well-known hallmark of JMML, it is more likely
a consequence favoring the granulo-monocytic expansion
than a causative abnormality in JMML-PCs. This is con-
sistent with the lack of activating GM-CSF mutation in
JMML [7–9] and suggests that a therapeutic strategy
antagonizing GM-CSF [13] might efﬁciently limit JMML
proliferation but probably not eradicate the disease.
Integration of the hematopoietic cellular hierarchy with
clonal evolution by analyzing isolated stem cell and pro-
genitor fractions, showed that the complete JMML muta-
tional proﬁle is already present with a high allelic burden in
the HSC/LMPP compartment, consistent with early clonal
dominance. In chronic myelomonocytic leukemia, an MPN
resembling JMML but occurring in adults [22], such an early
clonal dominance was also observed but the genetic diver-
sity captured by HSCs was shown to be lost in downstream
progenitor subsets due to systematic out-competition of a
dominant subclone in the GMP compartment [23]. In con-
trast, we show that in JMML, the mutational landscape as
well as the clonal equilibrium are stable throughout the
myeloid differentiation, even though the LMPP and GMP
compartments were ampliﬁed in a subset of patients. This
suggests that clonal selection occurred within the HSC/MPP
compartment very early in the oncogenic process and was
not affected by hematopoietic differentiation or expansion,
highlighting the stem cell origin of the JMML despite the
complexity of JMML-PCs.
Finally, this study highlighted an aberrant over-
expression of CD90 in a subset of patients. CD90/Thy-1 is a
cell surface glycoprotein involved in cell adhesion and cell
communication in numerous cell types. Although CD90 is
considered a major marker of HSC pluripotency and a
surrogate marker for HSCs, we could not evidence a higher
engraftment capacity in these CD90high JMML samples.
Further work will be needed to determine the potential
biological or clinical relevance of the upregulation of this
marker in some patients.
In conclusion, our data provides new evidence of JMML
heterogeneity, unveiling a complex clonal architecture and
different JMML-PCs. This heterogeneity could not be
explained by the pattern of genetic alterations nor by the
initiating cell in which mutations arise. In addition, we
show here that, by faithfully recapitulating both the key
clinical features and unbiased clonal architecture of the
disease, xenotransplanted mice could provide an invaluable
model for further research and testing of new candidate
treatments, which are urgently needed in this still mostly
incurable disease.
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